NCT06406465 2026-03-18
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
7 trialsNCT00993616 2019-07-23
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
National Cancer Institute (NCI)
Phase 2 Completed
NCT00301756 2018-08-20
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00365053 2018-06-07
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00357032 2018-04-17
PXD101 in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00589290 2015-09-30
Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00303953 2014-05-12
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed